Table 3.
Univariate analysis of survival rate for SCEC patients
| No. of cases | Survival rate (%,range) | ||||
|---|---|---|---|---|---|
| 1 year | 2 year | 3 year | 5 year | ||
| Total | 469 | 51.1 (41.3–67.2) | 25.5 (16.1–38.5) | 13.2 (6.4–23.3) | 7.9 (3.5–12) |
| Lymph node metastasis | |||||
| N0 | 45 | 31.1 (26.3–35.9) | 11.4 (5.2–17.6) | 5.3 (0–10.6) | |
| N+ | 84 | 77.3 (75–79.6) | 42 (33.3–50.7) | 28.6 (16.6–40.6) | |
| VALSG stage | |||||
| LD | 176 | 62.1 (59.4–64.7) | 31.2 (28.3–34.1) | 12.5 (5.1–19.8) | |
| ED | 17 | 39.5 (33.3–45.6) | 8.2 (0–16.4) | 0 | |
| TNM stage | |||||
| I | 16 | 80.0 | 66.7 | 33.3 | |
| IIa | 21 | 81.3 | 43.8 | 43.8 | |
| IIb | 23 | 58.2 | 25.5 | 12.7 | |
| III | 66 | 43.8 | 11.7 | 8.8 | |
| IV | 25 | 47.6 | 17.9 | 6.0 | |
| Treatment | |||||
| Local treatment | 39 | 28.9 (20–37.9) | 1.9 (0–3.8) | 0 | |
| Systemic treatment | 83 | 69.8 (50–89.5) | 38.1 (21.4–57.6) | 22.9 (11.7–40.0) | |
N0 lymph node negative, N+ lymph node positive, LD limited disease, ED extensive disease